Generate Biomedicines — Third Quarter 2026 Earnings Summary

Generate Biomedicines reported third-quarter 2026 financial results showing a net loss of $87.7 million and revenue of $4.2 million, with cash and marketable securities totaling $404.2 million as of September 30, 2026. The company advanced its lead candidate GB-0895, an AI-engineered anti-TSLP antibody, into two Phase 3 asthma studies and demonstrated sustained six-month pharmacological activity in COPD patients. Strategic partnerships were established with Zealand Pharma for a $30 million upfront payment to develop obesity therapeutics and with Anthropic to apply agentic AI to CAR T-cell research. Clinical progress included enrollment in the second cohort for GB-4362 in urothelial cancer and the first patient dosing for GB-5267 in ovarian cancer.